SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotechnology Value Fund, L.P. -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (696)6/9/1999 5:23:00 PM
From: scaram(o)ucheRespond to of 4974
 
Interesting turf battles today.... FDA versus Pfizer and Merck versus Pfizer. I guess that Merck has been saying that Vioxx has an advantage for pain relief in certain dental patients.

The company that can claim first advantage in a given clinical situation can have leverage for virtually all of them??

The Reuters release is interesting......
biz.yahoo.com

I didn't know that the dose of Celebrex (what a great sell job by the trade name guys/gals..... throw away your crutches and canes and dance, dance, dance!) was so much higher than that for Vioxx.

First blush IMO, advantage Merck. Lots of bucks on the line here...... hundreds of millions.



To: scaram(o)uche who wrote (696)6/9/1999 5:51:00 PM
From: scaram(o)ucheRespond to of 4974
 
I said......

>> I think I know why they have so many problems. <<

I believe that it's due to random bad luck. Not implying anything else.

I'd still switch to Vioxx. Why not? Is there a washout period at all? If Merck thinks they have an advantage..... can you move back and forth between these suckers as though they were aspirin and Ibuprofen?


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News